{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 42,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/18",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.139,
        "w": 0.932,
        "x": 0.034,
        "y": 0.694
      },
      "kind": "callout",
      "text": "Capivasertib plus fulvestrant has the potential to be a future treatment option for patients with HR+ ABC who have progressed on an endocrine-based regimen",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bfba60e-815f-4235-9f9e-1819b983b6ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.111,
        "w": 0.875,
        "x": 0.034,
        "y": 0.335
      },
      "kind": "list",
      "text": "Benefit from capivasertib was consistent across key clinically relevant subgroups, including in: Patients previously treated with CDK4/6 inhibitor; Patients with liver metastases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ba35aca-935c-4434-b098-1844a0cf0065",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.056,
        "w": 0.898,
        "x": 0.034,
        "y": 0.556
      },
      "kind": "list",
      "text": "Capivasertib plus fulvestrant safety profile appears consistent with that previously reported, with relatively low discontinuation rate due to adverse events",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7801c14-e414-4088-bb57-0cf717949c62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.028,
        "w": 0.385,
        "x": 0.034,
        "y": 0.505
      },
      "kind": "list",
      "text": "Overall survival follow-up is ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b28c31fd-718c-4060-9d3c-eb3fc441d496",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.083,
        "w": 0.875,
        "x": 0.034,
        "y": 0.235
      },
      "kind": "list",
      "text": "Capivasertib plus fulvestrant provides a statistically significant and clinically meaningful improvement in PFS in the overall and the AKT pathway-altered population (dual primary)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5c361b1-6a23-4097-861c-a41471cd58b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.056,
        "w": 0.692,
        "x": 0.034,
        "y": 0.065
      },
      "kind": "title",
      "text": "CAPItello-291: key takeaways and conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33801604-b610-4310-82d0-a73eca83da6c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 10,
      "beatId": "80040a4f-9dc5-4767-b554-f7b2a12bcc10",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "CAPItello-291 trial overview and data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1369eda6-1830-4169-af09-10a7f5fa7af1",
      "evidence": "CAPItello-291 trial data",
      "position": 2,
      "objective": "What is the potential of CAPItello-291?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}